person · Reporting owner
Fuglesang Christopher
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | See remarks | January 23, 2024 | January 25, 2024 |
| Tango Therapeutics, Inc.BCTG · Entity 1497 | Director · President | September 02, 2020 | September 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 25, 2024
Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, MVA Investors, LLC, Davis Aaron I., Dissanayake Shehan Bharatha, Braslyn Ltd., Lockend Five, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-01-23 · Disposition to issuer · Disposed 287,866 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-01-23 · Disposition to issuer · Disposed 203,754 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 3,135,966 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2024-01-23 · Disposition to issuer · Disposed 30,518 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-01-23 · Disposition to issuer · Disposed 3,201,440 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-23 · Disposition to issuer · Disposed 332,809 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-23 · Disposition to issuer · Disposed 3,578,036 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-23 · Disposition to issuer · Disposed 1,413,475 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").
F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.
F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.
F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.
F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.
F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.
Tango Therapeutics, Inc.
Report date September 02, 2020 · Filed September 03, 2020
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pandion Therapeutics, Inc.
Report date April 01, 2021 · Filed April 01, 2021
Section 16 reporting ended · disclosed 2021-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2021-04-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-04-01 · Other · Disposed 2,107,513 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), and indirectly by the reporting person, Boxer Management and Joe Lewis, by virtue of their ownership in Boxer Capital. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2021-04-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-04-01 · Other · Disposed 23,622 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F3: These securities are owned directly and solely by MVA Investors, LLC ("MVA Investors") which has sole voting and dispositive power with respect to these securities. The reporting person is a member of MVA Investors. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2030-07-16 | Direct | 0 |
Reported balance
After 2021-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-01 · Disposition to issuer · Disposed 13,997 · Balance 0 F5: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F4: All options were vested and exercisable as of immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), and indirectly by the reporting person, Boxer Management and Joe Lewis, by virtue of their ownership in Boxer Capital. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein.
F3: These securities are owned directly and solely by MVA Investors, LLC ("MVA Investors") which has sole voting and dispositive power with respect to these securities. The reporting person is a member of MVA Investors. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein.
F4: All options were vested and exercisable as of immediately prior to the Effective Time.
F5: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerWarrant (right to purchase) · Derivative | 1,413,475 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,413,475 shares Expires not disclosed F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerWarrant (right to purchase) · Derivative | 3,578,036 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · derivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 3,578,036 shares Expires not disclosed F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerWarrant (right to purchase) · Derivative | 332,809 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · derivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 332,809 shares Expires not disclosed F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 30,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F6 · ownership.nature: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 3,135,966 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 203,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F4 · ownership.nature: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 3,201,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 287,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:39 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 1,201,440 | $27.80 | $33,400,032.00 |
DisclosureSEC source: 0000895345-23-000500 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,201,440 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:39 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 57,533 | $27.80 | $1,599,417.40 |
DisclosureSEC source: 0000895345-23-000500 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 287,866 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. F1 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:38 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 1,201,440 | $27.80 | $33,400,032.00 |
DisclosureSEC source: 0000895345-23-000499 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,201,440 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:38 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 57,533 | $27.80 | $1,599,417.40 |
DisclosureSEC source: 0000895345-23-000499 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 287,866 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. F1 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 19:49 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 13,997 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-014452 · doc4.xml · derivative · entry 3 Fuglesang Christopher · CIK 0001465835 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,997 shares Expires 2030-07-16 F5 · price: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F4 · derivative.exercise_date: All options were vested and exercisable as of immediately prior to the Effective Time. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 19:49 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | OtherCommon Stock | 23,622 | $60.00 | $1,417,320.00 |
DisclosureSEC source: 0000899243-21-014452 · doc4.xml · nonDerivative · entry 2 Fuglesang Christopher · CIK 0001465835 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F3 · ownership.nature: These securities are owned directly and solely by MVA Investors, LLC ("MVA Investors") which has sole voting and dispositive power with respect to these securities. The reporting person is a member of MVA Investors. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 19:49 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | OtherCommon Stock | 2,107,513 | $60.00 | $126,450,780.00 |
DisclosureSEC source: 0000899243-21-014452 · doc4.xml · nonDerivative · entry 1 Fuglesang Christopher · CIK 0001465835 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F2 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), and indirectly by the reporting person, Boxer Management and Joe Lewis, by virtue of their ownership in Boxer Capital. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionWarrant (right to purchase) · Derivative | 468,639 | $13.00 Strike: $0.00 | $6,091,838.36 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · derivative · entry 9 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,809 Underlying: Common Stock · 468,639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionWarrant (right to purchase) · Derivative | 128,805 | $5.60 Strike: $0.00 | $721,179.20 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionWarrant (right to purchase) · Derivative | 13,996 | $5.60 Strike: $0.00 | $78,363.60 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · derivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,996 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 363,000 | $181.15 | $65,757,450.00 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 4 | $181.00 | $724.00 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363,000 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 597,444 | $0.00 | $597.44 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 37,000 | $181.15 | $6,702,550.00 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,333 F1 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1 | $181.00 | $181.00 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,333 F1 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:48 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 13,996 | $0.00 | $14.00 |
DisclosureSEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:54 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionWarrant (right to purchase) · Derivative | 37,051 | $5.60 Strike: $0.00 | $207,448.55 |
DisclosureSEC source: 0000899243-20-030060 · doc4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,996 Underlying: Common Stock · 37,051 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F3 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:54 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionWarrant (right to purchase) · Derivative | 362,952 | $5.60 Strike: $0.00 | $2,032,168.25 |
DisclosureSEC source: 0000899243-20-030060 · doc4.xml · derivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,805 Underlying: Common Stock · 362,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. F2 · ownership.direct: (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:54 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Tax withholdingCommon Stock | 2 | $219.97 | $439.94 |
DisclosureSEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,765,560 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. F2 · ownership.direct: (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:54 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 362,952 | $0.00 | $362.95 |
DisclosureSEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,765,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. F2 · ownership.direct: (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:54 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 362,950 | $202.00 | $73,315,900.00 |
DisclosureSEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,404,610 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. F2 · ownership.direct: (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:54 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Tax withholdingCommon Stock | 1 | $219.97 | $219.97 |
DisclosureSEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,338 F3 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:54 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 37,051 | $0.00 | $37.05 |
DisclosureSEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:54 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 37,050 | $202.00 | $7,484,100.00 |
DisclosureSEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,288 F3 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:44 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | ConversionSeries B Preferred Stock · Derivative | 7,184,596 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019882 · doc4.xml · derivative · entry 4 Fuglesang Christopher · CIK 0001465835 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,408,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.nature: These securities are owned directly by Boxer Capital, and indirectly by the reporting person, Boxer Management and Joe Lewis, by virtue of their ownership in Boxer Capital. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F4 · ownership.nature: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. The reporting person is a member of MVA Investors. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:44 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | PurchaseCommon Stock | 722,222 | $18.00 | $12,999,996.00 |
DisclosureSEC source: 0000899243-20-019882 · doc4.xml · nonDerivative · entry 2 Fuglesang Christopher · CIK 0001465835 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,600,773 F3 · ownership.nature: These securities are owned directly by Boxer Capital, and indirectly by the reporting person, Boxer Management and Joe Lewis, by virtue of their ownership in Boxer Capital. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:44 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | ConversionCommon Stock | 1,408,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019882 · doc4.xml · nonDerivative · entry 1 Fuglesang Christopher · CIK 0001465835 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,408,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Consists of 1,385,291 and 23,622 shares of Common Stock held by Boxer Capital, LLC ("Boxer Capital") and MVA Investors, LLC ("MVA Investors"), respectively. F2 · price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.nature: These securities are owned directly by Boxer Capital, and indirectly by the reporting person, Boxer Management and Joe Lewis, by virtue of their ownership in Boxer Capital. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F4 · ownership.nature: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. The reporting person is a member of MVA Investors. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 19:44 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | GrantStock Option (right to buy) · Derivative | 13,997 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019882 · doc4.xml · derivative · entry 3 Fuglesang Christopher · CIK 0001465835 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,997 Underlying: Common Stock · 13,997 shares Expires 2030-07-16 F5 · derivative.exercise_date: This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | OtherWarrant (right to purchase) · Derivative | 78,186 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0000899243-17-023345 · doc4.xml · derivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,186 shares Expires 2017-11-21 Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | OtherWarrant (right to purchase) · Derivative | 189,780 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0000899243-17-023345 · doc4.xml · derivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189,780 shares Expires 2017-11-21 Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | OtherCommon Stock | 78,186 | $7.86 | $614,541.96 |
DisclosureSEC source: 0000899243-17-023345 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,630 F2 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Lieberburg, Reisman, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | OtherCommon Stock | 189,780 | $7.86 | $1,491,670.80 |
DisclosureSEC source: 0000899243-17-023345 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227,774 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors"), (iv) Braslyn Ltd., (v) Joe Lewis, (vi) Christopher Fuglesang, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Neil Reisman, (x) Shehan B. Dissanayake, and (xi) Aaron I. Davis (collectively, the "Boxer Group"). Joseph C. Lewis is the sole indirect beneficial owner of and controls Braslyn Ltd. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 17:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseWarrant (right to purchase) · Derivative | 51,047 | $5.60 Strike: $0.00 | $285,812.15 |
DisclosureSEC source: 0000899243-17-000987 · doc4.xml · derivative · entry 9 Boxer Capital, LLC · CIK 0001465837 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner LAPPE RODNEY W · CIK 0001579826 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Reisman Neil · CIK 0001465834 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,047 Underlying: Common Stock · 51,047 shares Expires not disclosed F9 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F3 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 17:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseWarrant (right to purchase) · Derivative | 2,341,786 | $5.60 Strike: $0.00 | $13,111,659.81 |
DisclosureSEC source: 0000899243-17-000987 · doc4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner LAPPE RODNEY W · CIK 0001579826 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Reisman Neil · CIK 0001465834 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,341,786 Underlying: Common Stock · 2,341,786 shares Expires not disclosed F9 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Boxer Management and Messrs. F2 · ownership.direct: (Continued from Footnote 1) Lewis, Fuglesang, Reisman, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 17:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 6,104 | $5.60 | $34,182.40 |
DisclosureSEC source: 0000899243-17-000987 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner LAPPE RODNEY W · CIK 0001579826 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Reisman Neil · CIK 0001465834 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,444 F3 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 17:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 280,059 | $5.60 | $1,568,330.40 |
DisclosureSEC source: 0000899243-17-000987 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner LAPPE RODNEY W · CIK 0001579826 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Reisman Neil · CIK 0001465834 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,994 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Boxer Management and Messrs. F2 · ownership.direct: (Continued from Footnote 1) Lewis, Fuglesang, Reisman, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.